MNK (MNK) Stock News

Keenova (NASDAQ:MNK) announced it reached a milestone on Jan 21, 2026: 100,000 patients have been prescribed XIAFLEX to treat Peyronie's disease. XIAFLEX is described as the only FDA‑approved nonsurgical therapy for adult men with a palpable plaque and curvature >30 degrees at treatment start. Keenova plans expanded 2026 awareness campaigns, amplified patient voices on social media, and broader access to a mixed‑reality injection simulator for providers.

Keenova Therapeutics (NASDAQ:MNK) announced a Keenova‑sponsored presentation on Dupuytren's contracture (DC) at the American Association for Hand Surgery Annual Meeting, January 13–17, 2026. The presentation, led by Dr. Philip Blazar, reports results from a national patient survey on perceptions, attributes, and satisfaction with DC diagnosis and treatment options including surgery, collagenase clostridium histolyticum (CCH/XIAFLEX), and needle aponeurotomy.

The analysis highlights gaps in patient awareness and opportunities to improve education and patient–provider conversations to support earlier recognition and better treatment outcomes.

Keenova Therapeutics (NASDAQ:MNK) announced management will present at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 10:00 a.m. GMT (5:00 a.m. ET). A live webcast and archived replay will be available via the company’s Investor Relations website at www.keenova.com.

The presentation provides investors a scheduled opportunity to hear management commentary and view the webcast recording.

Mallinckrodt (NYSE:MNK) reported third-quarter 2025 combined net sales of $753.1 million, a 49.0% increase versus Q3 2024, reflecting two months of Endo inclusion and Acthar® Gel strength.

Specialty Brands sales were $416.0 million (45.5% growth), including Acthar Gel net sales of $181.4 million (+43.5%) and XIAFLEX net sales of $90.1 million. Generics and Sterile Injectables totaled $337.1 million (53.6% growth).

GAAP net loss was $291.1 million; adjusted EBITDA was $111.3 million. Management raised full-year Acthar Gel growth guidance to 30%–35% and provided Q4 2025 guidance of $485M–$505M net sales and $155M–$165M adjusted EBITDA. Post-merger synergy targets: $75M run-rate first 12 months and $150M by year three.

Keenova Therapeutics (formerly Mallinckrodt, NYSE: MNK) completed the spin-off of Par Health on Nov 10, 2025 and rebranded to focus on branded therapeutics for rare and unmet conditions.

The company reported a 2024 pro-forma combined revenue of $1.7 billion, employs >1,600 people, and lists flagship products Acthar Gel and XIAFLEX. Keenova is headquartered in Dublin with a U.S.-focused commercial and manufacturing footprint.

The company intends to pursue a NYSE listing in 2026 and expects to conduct a public offering to facilitate the listing, subject to board approval and other conditions.

Mallinckrodt (NYSE:MNK) will present four posters, including one AASLD Poster of Distinction, at The Liver Meeting (AASLD) in Washington, D.C., Nov 7–11, 2025.

Presentations focus on hepatorenal syndrome (HRS) and TERLIVAZ (terlipressin), the first FDA-approved therapy to improve kidney function in adults with HRS‑AKI. Session: Portal Hypertension and Other Complications of Cirrhosis on Nov 8, 2025. Poster numbers: #2285 (Distinction), #2401, #2315, #2380. Key prescribing notes: patients with serum creatinine >5 mg/dL are unlikely to benefit. Important safety: boxed warning for serious or fatal respiratory failure; contraindications include hypoxia and active ischemia.

Mallinckrodt (NYSE:MNK) will report its third quarter 2025 financial results on Monday, November 10, 2025 before market open.

The company will host a conference call the same day at 8:00 a.m. ET with an audio webcast available in the Investor Relations section at ir.mallinckrodt.com under Events & Presentations. Participants can register to receive a dial-in number and personalized PIN; attendees are advised to join 10 minutes early. A replay of the webcast will be available after the event.

Mallinckrodt (NYSE:MNK) announced support for the inaugural Hepatorenal Syndrome (HRS) Awareness Day, established by the American Liver Foundation and observed annually on October 14 during National Liver Awareness Month.

The initiative aims to raise awareness, promote early detection and treatment, and share patient experiences. HRS is described in two types: HRS‑AKI (rapid, often requiring hospitalization) and HRS‑CKD (slower progression). The release states HRS affects more than 60,000 Americans annually (~0.01% of the U.S. population) and that hospitalization rates for HRS are increasing. Company and ALF leaders commented on the need to improve visibility and treatment options for patients.

Mallinckrodt (NYSE:MNK) has published findings from a cross-sectional physician survey and medical chart review regarding Acthar® Gel treatment in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). The study, published in Open Access Rheumatology: Research and Reviews, demonstrated that some patients experienced positive treatment outcomes including reduced symptoms, decreased pain, improved physical function, and reduced corticosteroid use.

Acthar Gel, an FDA-approved complex mixture of ACTH analogs and pituitary peptides, is indicated for treating various autoimmune disorders and inflammatory conditions. The research provides valuable real-world data on the medication's clinical application and effectiveness in treating these complex arthritic conditions.